CD274 and melanoma: More importantly, longer follow-up data are needed to clarify the difference in response between melanomas with high and low PD-L1 expression, especially since the EMA has approved combination therapy with relatlimab and nivolumab only for the treatment of melanomas with PD-L1 expression of less than 1%.